Pharma Marketing’s New Frontier: Leveraging Content Subtype for Superior and Faster Reviews

 

Exploring the pivotal aspects of promotional content review in the pharmaceutical industry, the 2023 State of Promotional Review Benchmark Report presented in the Benchmarks Symposium series sheds light on the intricacies of job duration metrics by content subtype. Hosted by Annalise Ludtke, the Senior Manager of Marketing and Communications at Vodori , with the expertise of Dr. Joe DiCapite, the Director of Strategy at UK and Europe Vodori , this episode navigates through the diverse challenges and considerations involved in reviewing and approving various types of promotional content. Dr. DiCapite’s rich background in pharmaceuticals provides a detailed perspective on the importance of understanding these metrics for efficient planning and benchmarking against industry standards.

The discussion emphasizes how different content types, from social media to videos and podcasts, impact review durations and highlights the significance of such data for strategic planning and process improvement. By delving into factors that affect job duration, such as content complexity, size, and risk, the episode offers valuable insights into optimizing review processes. This analysis not only aids pharmaceutical companies in enhancing their promotional strategies but also ensures that critical medications are efficiently delivered to the right patients. The emphasis on content subtype highlights the strategic value of benchmark data in the promotional review process, providing a roadmap for enhancing efficiency and effectiveness in pharmaceutical marketing.

Recent Episodes

Generative AI has captured the public imagination, but its most transformative use cases may lie far from flashy consumer tools. In healthcare operations, where complexity, inefficiency, and fragmentation remain persistent challenges, AI is now driving measurable improvements. Research suggests AI-enabled healthcare systems could cut administrative costs by up to $360 billion in the U.S. alone….

Corganics is redefining standards in clinical cannabinoid care with THC-free, medical-grade CBD products developed for use exclusively by healthcare professionals. Backed by Advanced Lipid Technology, FDA-registered manufacturing, and rigorous third-party testing, Corganics offers a level of trust and transparency rare in the CBD space. In a conversation with Reggie Gatewood, President of Corganics, Brooke Williams,…

Corganics’ Clinical CBD Drops—THC-free, medical-grade, and developed with Advanced Lipid Technology—are designed for healthcare professionals seeking a trusted, science-backed cannabinoid solution for their patients. Manufactured in an FDA-registered facility and third-party lab-tested, these drops are a cornerstone of Corganics’ clinical approach. At Beautiphi Aesthetic Boutique, founder Kelly Hermans, CRNA, has integrated the drops into patient…